Inhibition of LSD1 Attenuates Oral Cancer Development and Promotes Therapeutic Efficacy of Immune Checkpoint Blockade and YAP/TAZ Inhibition.
Thabet AlhousamiMichael DinyFaiza AliJennifer ShinGaurav KumarVikas KumarJoshua D CampbellVikki NoonanGlenn J HannaGerald V DenisStephano MontiMaria A KukuruzinskaXaralabos VarelasManish V BaisPublished in: Molecular cancer research : MCR (2022)
Collectively, our studies reveal a critical role for LSD1 in OSCC development and identification of tumor growth targeting strategies that can be combined with LSD1 inhibition for improved therapeutic application.
Keyphrases